HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
26 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
PSMA5
proteasome 20S subunit alpha 5
Chromosome 1 · 1p13.3
NCBI Gene: 5686Ensembl: ENSG00000143106.14HGNC: HGNC:9534UniProt: A0A109NGN6
278PubMed Papers
20Diseases
6Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedHub Gene
RESEARCH IMPACT
Trending
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
structural constituent of proteasomeproteasomal protein catabolic processnucleuscytoplasmmultiple myelomaneoplasmMantle cell lymphomaHIV infection
✦AI Summary

PSMA5 encodes the α5 subunit of the 20S core proteasome, a critical component of the ubiquitin-proteasome system responsible for intracellular protein degradation 1. The protein forms part of the outer α-subunit rings that bind proteasome regulators and activators, with the refolded human PSMA5 existing primarily as a tetramer 2. PSMA5 participates in both ubiquitin-dependent protein degradation as part of the 26S proteasome complex and ubiquitin-independent degradation when associated with PA200 or PA28 regulatory particles 1. The gene shows significant disease relevance, with upregulation observed in lung adenocarcinoma where it promotes tumor progression through JAK/STAT pathway activation, correlating with poor prognosis and lymph node metastasis 3. Similarly, PSMA5 promotes tumorigenic processes in prostate cancer and is associated with bortezomib resistance 4. In glioblastoma, PSMA5 modulates cellular senescence and tumor growth, serving as both a prognostic biomarker and potential therapeutic target 5. Novel pathogenic variants in PSMA5 have been identified in proteasome-associated autoinflammatory syndromes (PRAAS), expanding the genetic spectrum of these conditions 6. These findings establish PSMA5 as clinically significant in cancer progression and inflammatory diseases.

Sources cited
1
PSMA5 encodes the α5 subunit of the 20S core proteasome involved in protein degradation
PMID: 22894781
2
Refolded human PSMA5 exists primarily as a tetramer and forms part of outer α-subunit rings
PMID: 15135414
3
PSMA5 upregulation in lung adenocarcinoma promotes tumor progression via JAK/STAT pathway
PMID: 35605971
4
PSMA5 promotes tumorigenic processes in prostate cancer and is associated with bortezomib resistance
PMID: 30807553
5
PSMA5 modulates cellular senescence and tumor growth in glioblastoma, serving as prognostic biomarker
PMID: 40597008
6
Novel pathogenic variants in PSMA5 identified in proteasome-associated autoinflammatory syndromes
PMID: 37600812
Disease Associationsⓘ20
multiple myelomaOpen Targets
0.60Moderate
neoplasmOpen Targets
0.51Moderate
Mantle cell lymphomaOpen Targets
0.50Moderate
HIV infectionOpen Targets
0.48Moderate
amyloidosisOpen Targets
0.37Weak
glioblastoma multiformeOpen Targets
0.28Weak
brain glioblastomaOpen Targets
0.26Weak
Varicose veinsOpen Targets
0.18Weak
neurodegenerative diseaseOpen Targets
0.16Weak
lymphomaOpen Targets
0.11Weak
Waldenstrom macroglobulinemiaOpen Targets
0.11Weak
non-Hodgkins lymphomaOpen Targets
0.11Weak
non-small cell lung carcinomaOpen Targets
0.10Weak
leukemiaOpen Targets
0.10Suggestive
AL amyloidosisOpen Targets
0.10Suggestive
acute myeloid leukemiaOpen Targets
0.09Suggestive
chronic graft versus host diseaseOpen Targets
0.09Suggestive
intelligenceOpen Targets
0.09Suggestive
gliomaOpen Targets
0.09Suggestive
cancerOpen Targets
0.08Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets6
BORTEZOMIB D-MANNITOLApproved
26S proteasome inhibitor
Mantle cell lymphoma
CARFILZOMIBApproved
26S proteasome inhibitor
multiple myeloma
IXAZOMIBApproved
26S proteasome inhibitor
multiple myeloma
IXAZOMIB CITRATEApproved
26S proteasome inhibitor
multiple myeloma
MARIZOMIBPhase III
20S proteasome inhibitor
brain glioblastoma
OPROZOMIBPhase II
26S proteasome inhibitor
Hodgkins lymphoma
Related Genes
PSMA3Protein interaction100%PSMA4Protein interaction100%PSMD8Protein interaction100%PSMC6Protein interaction100%POMPProtein interaction100%PSMC1Protein interaction100%
Tissue Expression6 tissues
Liver
100%
Brain
66%
Heart
60%
Lung
56%
Bone Marrow
42%
Ovary
34%
Gene Interaction Network
Click a node to explore
PSMA5PSMA3PSMA4PSMD8PSMC6POMPPSMC1
PROTEIN STRUCTURE
Preparing viewer…
PDB5LE5 · 1.80 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.32Highly Constrained
pLIⓘ
1.00Intolerant
Observed/Expected LoF0.12 [0.06–0.32]
RankingsWhere PSMA5 stands among ~20K protein-coding genes
  • #1,304of 20,598
    Most Researched278 · top 10%
  • #381of 1,025
    FDA-Approved Drug Targets4
  • #1,278of 17,882
    Most Constrained (LOEUF)0.32 · top 10%
Genes detectedPSMA5
Sources retrieved26 papers
Response time—
📄 Sources
26▼
1
Combined analysis of single-cell and bulk RNA sequencing reveals the expression patterns of circadian rhythm disruption in the immune microenvironment of Alzheimer's disease.
PMID: 37251379
Front Immunol · 2023
1.00
2
Polyclonal antibodies against human proteasome subunits PSMA3, PSMA5, and PSMB5.
PMID: 22894781
Hybridoma (Larchmt) · 2012
0.90
3
Brain and blood transcriptome-wide association studies identify five novel genes associated with Alzheimer's disease.
PMID: 40111921
J Alzheimers Dis · 2025
0.88
4
Purification and refolding of human alpha5-subunit (PSMA5) of the 20S proteasome, expressed as inclusion bodies in Escherichia coli.
PMID: 15135414
Protein Expr Purif · 2004
0.80
5
Identification of eight novel proteasome variants in five unrelated cases of proteasome-associated autoinflammatory syndromes (PRAAS).
PMID: 37600812
Front Immunol · 2023
0.70